99.4% PURITY LOT VL-2820-A Tirzepatide
A synthetic 39-amino-acid dual-pathway metabolic research peptide supplied as a 30 mg lyophilized vial for research into incretin signaling, glucose-dependent insulin secretion, and energy-balance regulation.
- 1 × Tirzepatide 30mg vial
- Tamper-evident flip-off cap
- Batch-tested for purity (≥99%)
- Lyophilized for stability during shipping
- Bacteriostatic water (3 mL)
About this compound
A synthetic 39-amino-acid dual-pathway metabolic research peptide supplied as a 30 mg lyophilized vial for research into incretin signaling, glucose-dependent insulin secretion, and energy-balance regulation.
- 30 mg lyophilized peptide per vial
- Dual-pathway metabolic peptide (LY3298176)
- Synthetic peptide, ≥99% purity
- Studied for incretin-receptor signaling and glucose-dependent insulin secretion
Why the lot matters
- Synthesized and tested per lot, never as a production-run average
- Certificate of Analysis published before the lot goes on sale
- Independent lab, contractually separate from manufacturing
What "research use only" means
This product is sold exclusively for in-vitro laboratory research. It is not evaluated by any medicines agency and is not intended for human or animal administration, diagnosis, treatment, or prevention of disease.
Technical data
Current lot snapshot
Shipping
Reported use in research
Tirzepatide is investigated as a dual-pathway metabolic research peptide, engaging two complementary incretin pathways. In preclinical models it is studied for its capacity to enhance glucose-dependent insulin secretion while modulating appetite and energy balance. Its engineered fatty-diacid moiety and amino-acid substitutions are examined for the extended half-life and once-weekly profile they confer in research systems. Investigators use it to probe incretin-receptor cross-talk, gastric-emptying dynamics, and central appetite-regulating pathways. The 30 mg vial supplies additional material for extended assay panels and higher working concentrations in laboratory settings.
Reported findings
Research reports that dual-pathway incretin co-activation produces greater reductions in glycemia and body weight than single-pathway activation in animal research models. In controlled clinical investigations, doses studied up to 15 mg weekly have been associated with substantial improvements in glycemic markers and reductions in body weight across the SURPASS and SURMOUNT programs. Preclinical studies describe enhanced insulin sensitivity, delayed gastric emptying, and reduced food intake following receptor activation. The 30 mg presentation is intended solely to provide more research material and higher working concentrations; it does not correspond to any characterized dose, and efficacy figures reported in the literature pertain only to the 5–15 mg range studied.
Handling & safety
The complete safety and toxicological profile of tirzepatide has not been completely characterized. In the published literature, metabolic research peptides of this class are associated with dose-dependent gastrointestinal effects and injection-site reactions across the ranges studied. This material is for laboratory research use only and is not for human or veterinary use. It should be handled only by qualified personnel using appropriate protective equipment and good laboratory practices.
Reconstitution
Recommended ratio
- 3 mL of bacteriostatic water per 30 mg vial
- Equivalent to 10 mg/mL (i.e. 1 mg per 10 units on a 100 U insulin syringe)
- Remove the plastic flip-off lid from the vial.
- Disinfect the rubber stoppers with alcohol wipes.
- Inject the diluent slowly down the inner wall of the vial to avoid foaming.
- Gently swirl the vial (never shake). Let it dissolve for about 10 minutes.
Storage
Unopened / before reconstitution
- Store at a stable temperature.
- Stable for 24 months.
- For long-term storage (2+ years), store at -20 °C.
Reconstituted solution
- Must be kept refrigerated.
- Avoid exposure to light and excessive heat.
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 4813.527 g/mol | PASS |
| Purity | HPLC (area %) | 99.4% | PASS |
| Net peptide content | Gravimetric | 29.91 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
3RD-PARTY LAB
| Parameter | Method | Result | Status |
|---|---|---|---|
| Identity confirmation | Mass spectrometry | Consistent with 4813.527 g/mol | PASS |
| Purity | HPLC (area %) | 99.5% | PASS |
| Net peptide content | Gravimetric | 29.88 mg | PASS |
| Appearance | Visual | White to off-white lyophilized powder | PASS |
| Residual solvents | GC headspace | Within limits | PASS |
| Microbial screening | Sterility panel | No growth detected | PASS |
| Lot | Filled | Purity | Report | Status | |
|---|---|---|---|---|---|
| VL-2820-A | Jul 2026 | 99.4% | TR-88314 | Active | |
| VL-2839-B | May 2026 | 99.5% | TR-88247 | Sold out |
